nodes	percent_of_prediction	percent_of_DWPC	metapath
Cevimeline—CYP2D6—Temsirolimus—kidney cancer	0.0854	0.169	CbGbCtD
Cevimeline—CYP3A4—Everolimus—kidney cancer	0.0804	0.159	CbGbCtD
Cevimeline—CYP3A4—Temsirolimus—kidney cancer	0.0543	0.108	CbGbCtD
Cevimeline—CYP2D6—Pazopanib—kidney cancer	0.0449	0.0889	CbGbCtD
Cevimeline—CYP2D6—Erlotinib—kidney cancer	0.032	0.0635	CbGbCtD
Cevimeline—CYP3A4—Pazopanib—kidney cancer	0.0285	0.0565	CbGbCtD
Cevimeline—CYP2D6—Sorafenib—kidney cancer	0.026	0.0516	CbGbCtD
Cevimeline—CYP2D6—Vinblastine—kidney cancer	0.0257	0.0509	CbGbCtD
Cevimeline—CHRM3—ureter—kidney cancer	0.0241	0.407	CbGeAlD
Cevimeline—CYP3A4—Erlotinib—kidney cancer	0.0204	0.0404	CbGbCtD
Cevimeline—CYP3A4—Paclitaxel—kidney cancer	0.0186	0.0369	CbGbCtD
Cevimeline—CYP3A4—Sorafenib—kidney cancer	0.0165	0.0328	CbGbCtD
Cevimeline—CYP3A4—Vinblastine—kidney cancer	0.0163	0.0324	CbGbCtD
Cevimeline—CYP3A4—Vincristine—kidney cancer	0.0161	0.0319	CbGbCtD
Cevimeline—CYP2D6—Doxorubicin—kidney cancer	0.0158	0.0313	CbGbCtD
Cevimeline—CYP3A4—Sunitinib—kidney cancer	0.0134	0.0266	CbGbCtD
Cevimeline—CYP3A4—Doxorubicin—kidney cancer	0.01	0.0199	CbGbCtD
Cevimeline—FMO1—nephron tubule—kidney cancer	0.00514	0.0866	CbGeAlD
Cevimeline—FMO1—renal system—kidney cancer	0.00467	0.0788	CbGeAlD
Cevimeline—FMO1—kidney—kidney cancer	0.00452	0.0761	CbGeAlD
Cevimeline—FMO1—cortex of kidney—kidney cancer	0.0044	0.0742	CbGeAlD
Cevimeline—CYP3A4—urine—kidney cancer	0.00431	0.0727	CbGeAlD
Cevimeline—CYP2D6—urine—kidney cancer	0.00424	0.0715	CbGeAlD
Cevimeline—CHRM3—renal system—kidney cancer	0.00192	0.0324	CbGeAlD
Cevimeline—CHRM3—kidney—kidney cancer	0.00186	0.0313	CbGeAlD
Cevimeline—CYP3A4—renal system—kidney cancer	0.00105	0.0178	CbGeAlD
Cevimeline—CYP2D6—renal system—kidney cancer	0.00104	0.0175	CbGeAlD
Cevimeline—CYP3A4—kidney—kidney cancer	0.00102	0.0172	CbGeAlD
Cevimeline—CYP2D6—kidney—kidney cancer	0.001	0.0169	CbGeAlD
Cevimeline—Chest pain—Paclitaxel—kidney cancer	9.79e-05	0.000238	CcSEcCtD
Cevimeline—Arthralgia—Paclitaxel—kidney cancer	9.79e-05	0.000238	CcSEcCtD
Cevimeline—Anxiety—Paclitaxel—kidney cancer	9.76e-05	0.000237	CcSEcCtD
Cevimeline—Face oedema—Doxorubicin—kidney cancer	9.76e-05	0.000237	CcSEcCtD
Cevimeline—Decreased appetite—Gemcitabine—kidney cancer	9.75e-05	0.000237	CcSEcCtD
Cevimeline—Hypersensitivity—Dactinomycin—kidney cancer	9.75e-05	0.000237	CcSEcCtD
Cevimeline—Chills—Capecitabine—kidney cancer	9.73e-05	0.000236	CcSEcCtD
Cevimeline—Arrhythmia—Capecitabine—kidney cancer	9.69e-05	0.000235	CcSEcCtD
Cevimeline—Discomfort—Paclitaxel—kidney cancer	9.68e-05	0.000235	CcSEcCtD
Cevimeline—Fatigue—Gemcitabine—kidney cancer	9.67e-05	0.000235	CcSEcCtD
Cevimeline—Gastrointestinal pain—Vincristine—kidney cancer	9.67e-05	0.000235	CcSEcCtD
Cevimeline—Dizziness—Sorafenib—kidney cancer	9.6e-05	0.000233	CcSEcCtD
Cevimeline—Constipation—Gemcitabine—kidney cancer	9.59e-05	0.000233	CcSEcCtD
Cevimeline—Pain—Gemcitabine—kidney cancer	9.59e-05	0.000233	CcSEcCtD
Cevimeline—Nausea—Erlotinib—kidney cancer	9.59e-05	0.000233	CcSEcCtD
Cevimeline—Alopecia—Capecitabine—kidney cancer	9.58e-05	0.000233	CcSEcCtD
Cevimeline—Mood swings—Doxorubicin—kidney cancer	9.57e-05	0.000233	CcSEcCtD
Cevimeline—Diarrhoea—Sunitinib—kidney cancer	9.56e-05	0.000232	CcSEcCtD
Cevimeline—Asthenia—Dactinomycin—kidney cancer	9.49e-05	0.000231	CcSEcCtD
Cevimeline—Confusional state—Paclitaxel—kidney cancer	9.47e-05	0.00023	CcSEcCtD
Cevimeline—Malnutrition—Capecitabine—kidney cancer	9.44e-05	0.000229	CcSEcCtD
Cevimeline—Dehydration—Doxorubicin—kidney cancer	9.4e-05	0.000228	CcSEcCtD
Cevimeline—Oedema—Paclitaxel—kidney cancer	9.39e-05	0.000228	CcSEcCtD
Cevimeline—Body temperature increased—Vincristine—kidney cancer	9.34e-05	0.000227	CcSEcCtD
Cevimeline—Abdominal pain—Vincristine—kidney cancer	9.34e-05	0.000227	CcSEcCtD
Cevimeline—Infection—Paclitaxel—kidney cancer	9.33e-05	0.000227	CcSEcCtD
Cevimeline—Flatulence—Capecitabine—kidney cancer	9.3e-05	0.000226	CcSEcCtD
Cevimeline—Dry skin—Doxorubicin—kidney cancer	9.26e-05	0.000225	CcSEcCtD
Cevimeline—Dysgeusia—Capecitabine—kidney cancer	9.24e-05	0.000225	CcSEcCtD
Cevimeline—Dizziness—Sunitinib—kidney cancer	9.24e-05	0.000224	CcSEcCtD
Cevimeline—Feeling abnormal—Gemcitabine—kidney cancer	9.24e-05	0.000224	CcSEcCtD
Cevimeline—Shock—Paclitaxel—kidney cancer	9.24e-05	0.000224	CcSEcCtD
Cevimeline—Vomiting—Sorafenib—kidney cancer	9.23e-05	0.000224	CcSEcCtD
Cevimeline—Orthostatic hypotension—Doxorubicin—kidney cancer	9.23e-05	0.000224	CcSEcCtD
Cevimeline—Nervous system disorder—Paclitaxel—kidney cancer	9.21e-05	0.000224	CcSEcCtD
Cevimeline—Hypokalaemia—Doxorubicin—kidney cancer	9.2e-05	0.000223	CcSEcCtD
Cevimeline—Thrombocytopenia—Paclitaxel—kidney cancer	9.19e-05	0.000223	CcSEcCtD
Cevimeline—Tachycardia—Paclitaxel—kidney cancer	9.16e-05	0.000223	CcSEcCtD
Cevimeline—Rash—Sorafenib—kidney cancer	9.16e-05	0.000222	CcSEcCtD
Cevimeline—Dermatitis—Sorafenib—kidney cancer	9.15e-05	0.000222	CcSEcCtD
Cevimeline—Back pain—Capecitabine—kidney cancer	9.13e-05	0.000222	CcSEcCtD
Cevimeline—Skin disorder—Paclitaxel—kidney cancer	9.12e-05	0.000222	CcSEcCtD
Cevimeline—Headache—Sorafenib—kidney cancer	9.1e-05	0.000221	CcSEcCtD
Cevimeline—Muscle spasms—Capecitabine—kidney cancer	9.08e-05	0.00022	CcSEcCtD
Cevimeline—Hyperhidrosis—Paclitaxel—kidney cancer	9.08e-05	0.00022	CcSEcCtD
Cevimeline—Diarrhoea—Dactinomycin—kidney cancer	9.05e-05	0.00022	CcSEcCtD
Cevimeline—Anorexia—Paclitaxel—kidney cancer	8.95e-05	0.000217	CcSEcCtD
Cevimeline—Gastritis—Doxorubicin—kidney cancer	8.94e-05	0.000217	CcSEcCtD
Cevimeline—Muscular weakness—Doxorubicin—kidney cancer	8.91e-05	0.000216	CcSEcCtD
Cevimeline—Alanine aminotransferase increased—Doxorubicin—kidney cancer	8.91e-05	0.000216	CcSEcCtD
Cevimeline—Vomiting—Sunitinib—kidney cancer	8.89e-05	0.000216	CcSEcCtD
Cevimeline—Body temperature increased—Gemcitabine—kidney cancer	8.86e-05	0.000215	CcSEcCtD
Cevimeline—Tremor—Capecitabine—kidney cancer	8.84e-05	0.000215	CcSEcCtD
Cevimeline—Rash—Sunitinib—kidney cancer	8.81e-05	0.000214	CcSEcCtD
Cevimeline—Dermatitis—Sunitinib—kidney cancer	8.8e-05	0.000214	CcSEcCtD
Cevimeline—Abdominal distension—Doxorubicin—kidney cancer	8.79e-05	0.000214	CcSEcCtD
Cevimeline—Hypotension—Paclitaxel—kidney cancer	8.77e-05	0.000213	CcSEcCtD
Cevimeline—Ill-defined disorder—Capecitabine—kidney cancer	8.76e-05	0.000213	CcSEcCtD
Cevimeline—Headache—Sunitinib—kidney cancer	8.76e-05	0.000213	CcSEcCtD
Cevimeline—Dysphagia—Doxorubicin—kidney cancer	8.73e-05	0.000212	CcSEcCtD
Cevimeline—Asthma—Doxorubicin—kidney cancer	8.73e-05	0.000212	CcSEcCtD
Cevimeline—Anaemia—Capecitabine—kidney cancer	8.73e-05	0.000212	CcSEcCtD
Cevimeline—Hypersensitivity—Vincristine—kidney cancer	8.71e-05	0.000212	CcSEcCtD
Cevimeline—Eosinophilia—Doxorubicin—kidney cancer	8.65e-05	0.00021	CcSEcCtD
Cevimeline—Nausea—Sorafenib—kidney cancer	8.63e-05	0.00021	CcSEcCtD
Cevimeline—Musculoskeletal discomfort—Paclitaxel—kidney cancer	8.55e-05	0.000208	CcSEcCtD
Cevimeline—Malaise—Capecitabine—kidney cancer	8.51e-05	0.000207	CcSEcCtD
Cevimeline—Angina pectoris—Doxorubicin—kidney cancer	8.51e-05	0.000207	CcSEcCtD
Cevimeline—Insomnia—Paclitaxel—kidney cancer	8.49e-05	0.000206	CcSEcCtD
Cevimeline—Vertigo—Capecitabine—kidney cancer	8.48e-05	0.000206	CcSEcCtD
Cevimeline—Asthenia—Vincristine—kidney cancer	8.48e-05	0.000206	CcSEcCtD
Cevimeline—Syncope—Capecitabine—kidney cancer	8.47e-05	0.000206	CcSEcCtD
Cevimeline—Leukopenia—Capecitabine—kidney cancer	8.45e-05	0.000205	CcSEcCtD
Cevimeline—Paraesthesia—Paclitaxel—kidney cancer	8.43e-05	0.000205	CcSEcCtD
Cevimeline—Vomiting—Dactinomycin—kidney cancer	8.41e-05	0.000204	CcSEcCtD
Cevimeline—Bronchitis—Doxorubicin—kidney cancer	8.4e-05	0.000204	CcSEcCtD
Cevimeline—Dyspnoea—Paclitaxel—kidney cancer	8.37e-05	0.000203	CcSEcCtD
Cevimeline—Somnolence—Paclitaxel—kidney cancer	8.35e-05	0.000203	CcSEcCtD
Cevimeline—Palpitations—Capecitabine—kidney cancer	8.34e-05	0.000203	CcSEcCtD
Cevimeline—Rash—Dactinomycin—kidney cancer	8.34e-05	0.000203	CcSEcCtD
Cevimeline—Nausea—Sunitinib—kidney cancer	8.3e-05	0.000202	CcSEcCtD
Cevimeline—Loss of consciousness—Capecitabine—kidney cancer	8.3e-05	0.000202	CcSEcCtD
Cevimeline—Dyspepsia—Paclitaxel—kidney cancer	8.26e-05	0.000201	CcSEcCtD
Cevimeline—Cough—Capecitabine—kidney cancer	8.24e-05	0.0002	CcSEcCtD
Cevimeline—Dysuria—Doxorubicin—kidney cancer	8.17e-05	0.000198	CcSEcCtD
Cevimeline—Decreased appetite—Paclitaxel—kidney cancer	8.16e-05	0.000198	CcSEcCtD
Cevimeline—Hypertension—Capecitabine—kidney cancer	8.15e-05	0.000198	CcSEcCtD
Cevimeline—Upper respiratory tract infection—Doxorubicin—kidney cancer	8.12e-05	0.000197	CcSEcCtD
Cevimeline—Fatigue—Paclitaxel—kidney cancer	8.09e-05	0.000197	CcSEcCtD
Cevimeline—Diarrhoea—Vincristine—kidney cancer	8.09e-05	0.000196	CcSEcCtD
Cevimeline—Pollakiuria—Doxorubicin—kidney cancer	8.07e-05	0.000196	CcSEcCtD
Cevimeline—Asthenia—Gemcitabine—kidney cancer	8.05e-05	0.000195	CcSEcCtD
Cevimeline—Arthralgia—Capecitabine—kidney cancer	8.04e-05	0.000195	CcSEcCtD
Cevimeline—Chest pain—Capecitabine—kidney cancer	8.04e-05	0.000195	CcSEcCtD
Cevimeline—Myalgia—Capecitabine—kidney cancer	8.04e-05	0.000195	CcSEcCtD
Cevimeline—Constipation—Paclitaxel—kidney cancer	8.03e-05	0.000195	CcSEcCtD
Cevimeline—Pain—Paclitaxel—kidney cancer	8.03e-05	0.000195	CcSEcCtD
Cevimeline—Anxiety—Capecitabine—kidney cancer	8.01e-05	0.000195	CcSEcCtD
Cevimeline—Photosensitivity reaction—Doxorubicin—kidney cancer	7.97e-05	0.000194	CcSEcCtD
Cevimeline—Weight increased—Doxorubicin—kidney cancer	7.95e-05	0.000193	CcSEcCtD
Cevimeline—Discomfort—Capecitabine—kidney cancer	7.94e-05	0.000193	CcSEcCtD
Cevimeline—Pruritus—Gemcitabine—kidney cancer	7.93e-05	0.000193	CcSEcCtD
Cevimeline—Weight decreased—Doxorubicin—kidney cancer	7.9e-05	0.000192	CcSEcCtD
Cevimeline—Hyperglycaemia—Doxorubicin—kidney cancer	7.88e-05	0.000191	CcSEcCtD
Cevimeline—Nausea—Dactinomycin—kidney cancer	7.86e-05	0.000191	CcSEcCtD
Cevimeline—Pneumonia—Doxorubicin—kidney cancer	7.83e-05	0.00019	CcSEcCtD
Cevimeline—Dizziness—Vincristine—kidney cancer	7.82e-05	0.00019	CcSEcCtD
Cevimeline—Confusional state—Capecitabine—kidney cancer	7.77e-05	0.000189	CcSEcCtD
Cevimeline—Feeling abnormal—Paclitaxel—kidney cancer	7.74e-05	0.000188	CcSEcCtD
Cevimeline—Oedema—Capecitabine—kidney cancer	7.7e-05	0.000187	CcSEcCtD
Cevimeline—Gastrointestinal pain—Paclitaxel—kidney cancer	7.68e-05	0.000186	CcSEcCtD
Cevimeline—Diarrhoea—Gemcitabine—kidney cancer	7.67e-05	0.000186	CcSEcCtD
Cevimeline—Infection—Capecitabine—kidney cancer	7.65e-05	0.000186	CcSEcCtD
Cevimeline—Neuropathy peripheral—Doxorubicin—kidney cancer	7.63e-05	0.000185	CcSEcCtD
Cevimeline—Stomatitis—Doxorubicin—kidney cancer	7.59e-05	0.000184	CcSEcCtD
Cevimeline—Shock—Capecitabine—kidney cancer	7.58e-05	0.000184	CcSEcCtD
Cevimeline—Conjunctivitis—Doxorubicin—kidney cancer	7.57e-05	0.000184	CcSEcCtD
Cevimeline—Urinary tract infection—Doxorubicin—kidney cancer	7.57e-05	0.000184	CcSEcCtD
Cevimeline—Nervous system disorder—Capecitabine—kidney cancer	7.56e-05	0.000184	CcSEcCtD
Cevimeline—Thrombocytopenia—Capecitabine—kidney cancer	7.54e-05	0.000183	CcSEcCtD
Cevimeline—Tachycardia—Capecitabine—kidney cancer	7.52e-05	0.000183	CcSEcCtD
Cevimeline—Vomiting—Vincristine—kidney cancer	7.52e-05	0.000183	CcSEcCtD
Cevimeline—Skin disorder—Capecitabine—kidney cancer	7.48e-05	0.000182	CcSEcCtD
Cevimeline—Urticaria—Paclitaxel—kidney cancer	7.46e-05	0.000181	CcSEcCtD
Cevimeline—Rash—Vincristine—kidney cancer	7.45e-05	0.000181	CcSEcCtD
Cevimeline—Hyperhidrosis—Capecitabine—kidney cancer	7.45e-05	0.000181	CcSEcCtD
Cevimeline—Dermatitis—Vincristine—kidney cancer	7.45e-05	0.000181	CcSEcCtD
Cevimeline—Haematuria—Doxorubicin—kidney cancer	7.42e-05	0.00018	CcSEcCtD
Cevimeline—Abdominal pain—Paclitaxel—kidney cancer	7.42e-05	0.00018	CcSEcCtD
Cevimeline—Body temperature increased—Paclitaxel—kidney cancer	7.42e-05	0.00018	CcSEcCtD
Cevimeline—Headache—Vincristine—kidney cancer	7.41e-05	0.00018	CcSEcCtD
Cevimeline—Epistaxis—Doxorubicin—kidney cancer	7.35e-05	0.000178	CcSEcCtD
Cevimeline—Anorexia—Capecitabine—kidney cancer	7.34e-05	0.000178	CcSEcCtD
Cevimeline—Sinusitis—Doxorubicin—kidney cancer	7.31e-05	0.000177	CcSEcCtD
Cevimeline—Agranulocytosis—Doxorubicin—kidney cancer	7.27e-05	0.000177	CcSEcCtD
Cevimeline—Hypotension—Capecitabine—kidney cancer	7.2e-05	0.000175	CcSEcCtD
Cevimeline—Vomiting—Gemcitabine—kidney cancer	7.13e-05	0.000173	CcSEcCtD
Cevimeline—Rash—Gemcitabine—kidney cancer	7.07e-05	0.000172	CcSEcCtD
Cevimeline—Dermatitis—Gemcitabine—kidney cancer	7.06e-05	0.000172	CcSEcCtD
Cevimeline—Haemoglobin—Doxorubicin—kidney cancer	7.03e-05	0.000171	CcSEcCtD
Cevimeline—Headache—Gemcitabine—kidney cancer	7.03e-05	0.000171	CcSEcCtD
Cevimeline—Nausea—Vincristine—kidney cancer	7.02e-05	0.000171	CcSEcCtD
Cevimeline—Musculoskeletal discomfort—Capecitabine—kidney cancer	7.02e-05	0.000171	CcSEcCtD
Cevimeline—Rhinitis—Doxorubicin—kidney cancer	7.01e-05	0.00017	CcSEcCtD
Cevimeline—Haemorrhage—Doxorubicin—kidney cancer	6.99e-05	0.00017	CcSEcCtD
Cevimeline—Insomnia—Capecitabine—kidney cancer	6.97e-05	0.000169	CcSEcCtD
Cevimeline—Hypoaesthesia—Doxorubicin—kidney cancer	6.96e-05	0.000169	CcSEcCtD
Cevimeline—Pharyngitis—Doxorubicin—kidney cancer	6.94e-05	0.000169	CcSEcCtD
Cevimeline—Paraesthesia—Capecitabine—kidney cancer	6.92e-05	0.000168	CcSEcCtD
Cevimeline—Hypersensitivity—Paclitaxel—kidney cancer	6.92e-05	0.000168	CcSEcCtD
Cevimeline—Oedema peripheral—Doxorubicin—kidney cancer	6.89e-05	0.000167	CcSEcCtD
Cevimeline—Dyspnoea—Capecitabine—kidney cancer	6.87e-05	0.000167	CcSEcCtD
Cevimeline—Urethral disorder—Doxorubicin—kidney cancer	6.85e-05	0.000166	CcSEcCtD
Cevimeline—Dyspepsia—Capecitabine—kidney cancer	6.78e-05	0.000165	CcSEcCtD
Cevimeline—Visual impairment—Doxorubicin—kidney cancer	6.74e-05	0.000164	CcSEcCtD
Cevimeline—Asthenia—Paclitaxel—kidney cancer	6.74e-05	0.000164	CcSEcCtD
Cevimeline—Decreased appetite—Capecitabine—kidney cancer	6.7e-05	0.000163	CcSEcCtD
Cevimeline—Nausea—Gemcitabine—kidney cancer	6.66e-05	0.000162	CcSEcCtD
Cevimeline—Fatigue—Capecitabine—kidney cancer	6.64e-05	0.000161	CcSEcCtD
Cevimeline—Pruritus—Paclitaxel—kidney cancer	6.64e-05	0.000161	CcSEcCtD
Cevimeline—Pain—Capecitabine—kidney cancer	6.59e-05	0.00016	CcSEcCtD
Cevimeline—Constipation—Capecitabine—kidney cancer	6.59e-05	0.00016	CcSEcCtD
Cevimeline—Eye disorder—Doxorubicin—kidney cancer	6.53e-05	0.000159	CcSEcCtD
Cevimeline—Tinnitus—Doxorubicin—kidney cancer	6.52e-05	0.000158	CcSEcCtD
Cevimeline—Cardiac disorder—Doxorubicin—kidney cancer	6.49e-05	0.000158	CcSEcCtD
Cevimeline—Flushing—Doxorubicin—kidney cancer	6.49e-05	0.000158	CcSEcCtD
Cevimeline—Diarrhoea—Paclitaxel—kidney cancer	6.42e-05	0.000156	CcSEcCtD
Cevimeline—Feeling abnormal—Capecitabine—kidney cancer	6.35e-05	0.000154	CcSEcCtD
Cevimeline—Angiopathy—Doxorubicin—kidney cancer	6.34e-05	0.000154	CcSEcCtD
Cevimeline—Gastrointestinal pain—Capecitabine—kidney cancer	6.3e-05	0.000153	CcSEcCtD
Cevimeline—Chills—Doxorubicin—kidney cancer	6.27e-05	0.000152	CcSEcCtD
Cevimeline—Arrhythmia—Doxorubicin—kidney cancer	6.24e-05	0.000152	CcSEcCtD
Cevimeline—Dizziness—Paclitaxel—kidney cancer	6.21e-05	0.000151	CcSEcCtD
Cevimeline—Alopecia—Doxorubicin—kidney cancer	6.18e-05	0.00015	CcSEcCtD
Cevimeline—Urticaria—Capecitabine—kidney cancer	6.12e-05	0.000149	CcSEcCtD
Cevimeline—Body temperature increased—Capecitabine—kidney cancer	6.09e-05	0.000148	CcSEcCtD
Cevimeline—Abdominal pain—Capecitabine—kidney cancer	6.09e-05	0.000148	CcSEcCtD
Cevimeline—Malnutrition—Doxorubicin—kidney cancer	6.09e-05	0.000148	CcSEcCtD
Cevimeline—Flatulence—Doxorubicin—kidney cancer	6e-05	0.000146	CcSEcCtD
Cevimeline—Vomiting—Paclitaxel—kidney cancer	5.97e-05	0.000145	CcSEcCtD
Cevimeline—Dysgeusia—Doxorubicin—kidney cancer	5.96e-05	0.000145	CcSEcCtD
Cevimeline—Rash—Paclitaxel—kidney cancer	5.92e-05	0.000144	CcSEcCtD
Cevimeline—Dermatitis—Paclitaxel—kidney cancer	5.91e-05	0.000144	CcSEcCtD
Cevimeline—Back pain—Doxorubicin—kidney cancer	5.89e-05	0.000143	CcSEcCtD
Cevimeline—Headache—Paclitaxel—kidney cancer	5.88e-05	0.000143	CcSEcCtD
Cevimeline—Muscle spasms—Doxorubicin—kidney cancer	5.85e-05	0.000142	CcSEcCtD
Cevimeline—Hypersensitivity—Capecitabine—kidney cancer	5.68e-05	0.000138	CcSEcCtD
Cevimeline—Ill-defined disorder—Doxorubicin—kidney cancer	5.65e-05	0.000137	CcSEcCtD
Cevimeline—Anaemia—Doxorubicin—kidney cancer	5.62e-05	0.000137	CcSEcCtD
Cevimeline—Agitation—Doxorubicin—kidney cancer	5.59e-05	0.000136	CcSEcCtD
Cevimeline—Nausea—Paclitaxel—kidney cancer	5.58e-05	0.000135	CcSEcCtD
Cevimeline—Asthenia—Capecitabine—kidney cancer	5.53e-05	0.000134	CcSEcCtD
Cevimeline—Malaise—Doxorubicin—kidney cancer	5.49e-05	0.000133	CcSEcCtD
Cevimeline—Vertigo—Doxorubicin—kidney cancer	5.47e-05	0.000133	CcSEcCtD
Cevimeline—Syncope—Doxorubicin—kidney cancer	5.46e-05	0.000133	CcSEcCtD
Cevimeline—Pruritus—Capecitabine—kidney cancer	5.45e-05	0.000132	CcSEcCtD
Cevimeline—Leukopenia—Doxorubicin—kidney cancer	5.45e-05	0.000132	CcSEcCtD
Cevimeline—Palpitations—Doxorubicin—kidney cancer	5.38e-05	0.000131	CcSEcCtD
Cevimeline—Loss of consciousness—Doxorubicin—kidney cancer	5.35e-05	0.00013	CcSEcCtD
Cevimeline—Cough—Doxorubicin—kidney cancer	5.31e-05	0.000129	CcSEcCtD
Cevimeline—Convulsion—Doxorubicin—kidney cancer	5.27e-05	0.000128	CcSEcCtD
Cevimeline—Diarrhoea—Capecitabine—kidney cancer	5.27e-05	0.000128	CcSEcCtD
Cevimeline—Hypertension—Doxorubicin—kidney cancer	5.25e-05	0.000128	CcSEcCtD
Cevimeline—Arthralgia—Doxorubicin—kidney cancer	5.18e-05	0.000126	CcSEcCtD
Cevimeline—Myalgia—Doxorubicin—kidney cancer	5.18e-05	0.000126	CcSEcCtD
Cevimeline—Chest pain—Doxorubicin—kidney cancer	5.18e-05	0.000126	CcSEcCtD
Cevimeline—Anxiety—Doxorubicin—kidney cancer	5.16e-05	0.000125	CcSEcCtD
Cevimeline—Discomfort—Doxorubicin—kidney cancer	5.12e-05	0.000124	CcSEcCtD
Cevimeline—Dizziness—Capecitabine—kidney cancer	5.1e-05	0.000124	CcSEcCtD
Cevimeline—Confusional state—Doxorubicin—kidney cancer	5.01e-05	0.000122	CcSEcCtD
Cevimeline—Oedema—Doxorubicin—kidney cancer	4.97e-05	0.000121	CcSEcCtD
Cevimeline—Infection—Doxorubicin—kidney cancer	4.93e-05	0.00012	CcSEcCtD
Cevimeline—Vomiting—Capecitabine—kidney cancer	4.9e-05	0.000119	CcSEcCtD
Cevimeline—Shock—Doxorubicin—kidney cancer	4.89e-05	0.000119	CcSEcCtD
Cevimeline—Nervous system disorder—Doxorubicin—kidney cancer	4.87e-05	0.000118	CcSEcCtD
Cevimeline—Thrombocytopenia—Doxorubicin—kidney cancer	4.86e-05	0.000118	CcSEcCtD
Cevimeline—Rash—Capecitabine—kidney cancer	4.86e-05	0.000118	CcSEcCtD
Cevimeline—Dermatitis—Capecitabine—kidney cancer	4.85e-05	0.000118	CcSEcCtD
Cevimeline—Tachycardia—Doxorubicin—kidney cancer	4.85e-05	0.000118	CcSEcCtD
Cevimeline—Headache—Capecitabine—kidney cancer	4.83e-05	0.000117	CcSEcCtD
Cevimeline—Skin disorder—Doxorubicin—kidney cancer	4.82e-05	0.000117	CcSEcCtD
Cevimeline—Hyperhidrosis—Doxorubicin—kidney cancer	4.8e-05	0.000117	CcSEcCtD
Cevimeline—Anorexia—Doxorubicin—kidney cancer	4.73e-05	0.000115	CcSEcCtD
Cevimeline—Hypotension—Doxorubicin—kidney cancer	4.64e-05	0.000113	CcSEcCtD
Cevimeline—Nausea—Capecitabine—kidney cancer	4.58e-05	0.000111	CcSEcCtD
Cevimeline—Musculoskeletal discomfort—Doxorubicin—kidney cancer	4.52e-05	0.00011	CcSEcCtD
Cevimeline—Insomnia—Doxorubicin—kidney cancer	4.49e-05	0.000109	CcSEcCtD
Cevimeline—Paraesthesia—Doxorubicin—kidney cancer	4.46e-05	0.000108	CcSEcCtD
Cevimeline—Dyspnoea—Doxorubicin—kidney cancer	4.43e-05	0.000108	CcSEcCtD
Cevimeline—Somnolence—Doxorubicin—kidney cancer	4.42e-05	0.000107	CcSEcCtD
Cevimeline—Dyspepsia—Doxorubicin—kidney cancer	4.37e-05	0.000106	CcSEcCtD
Cevimeline—Decreased appetite—Doxorubicin—kidney cancer	4.32e-05	0.000105	CcSEcCtD
Cevimeline—Fatigue—Doxorubicin—kidney cancer	4.28e-05	0.000104	CcSEcCtD
Cevimeline—Constipation—Doxorubicin—kidney cancer	4.25e-05	0.000103	CcSEcCtD
Cevimeline—Pain—Doxorubicin—kidney cancer	4.25e-05	0.000103	CcSEcCtD
Cevimeline—Feeling abnormal—Doxorubicin—kidney cancer	4.09e-05	9.94e-05	CcSEcCtD
Cevimeline—Gastrointestinal pain—Doxorubicin—kidney cancer	4.06e-05	9.86e-05	CcSEcCtD
Cevimeline—Urticaria—Doxorubicin—kidney cancer	3.95e-05	9.58e-05	CcSEcCtD
Cevimeline—Body temperature increased—Doxorubicin—kidney cancer	3.93e-05	9.54e-05	CcSEcCtD
Cevimeline—Abdominal pain—Doxorubicin—kidney cancer	3.93e-05	9.54e-05	CcSEcCtD
Cevimeline—Hypersensitivity—Doxorubicin—kidney cancer	3.66e-05	8.89e-05	CcSEcCtD
Cevimeline—Asthenia—Doxorubicin—kidney cancer	3.56e-05	8.66e-05	CcSEcCtD
Cevimeline—Pruritus—Doxorubicin—kidney cancer	3.51e-05	8.54e-05	CcSEcCtD
Cevimeline—Diarrhoea—Doxorubicin—kidney cancer	3.4e-05	8.25e-05	CcSEcCtD
Cevimeline—Dizziness—Doxorubicin—kidney cancer	3.28e-05	7.98e-05	CcSEcCtD
Cevimeline—Vomiting—Doxorubicin—kidney cancer	3.16e-05	7.67e-05	CcSEcCtD
Cevimeline—Rash—Doxorubicin—kidney cancer	3.13e-05	7.61e-05	CcSEcCtD
Cevimeline—Dermatitis—Doxorubicin—kidney cancer	3.13e-05	7.6e-05	CcSEcCtD
Cevimeline—Headache—Doxorubicin—kidney cancer	3.11e-05	7.56e-05	CcSEcCtD
Cevimeline—Nausea—Doxorubicin—kidney cancer	2.95e-05	7.17e-05	CcSEcCtD
Cevimeline—CHRM3—Signaling Pathways—AMER1—kidney cancer	2.87e-05	0.00116	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—ACY1—kidney cancer	2.83e-05	0.00115	CbGpPWpGaD
Cevimeline—CHRM1—Signaling by GPCR—AKAP13—kidney cancer	2.79e-05	0.00114	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—CA2—kidney cancer	2.79e-05	0.00114	CbGpPWpGaD
Cevimeline—CHRM3—Signaling by GPCR—AKAP13—kidney cancer	2.79e-05	0.00113	CbGpPWpGaD
Cevimeline—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—RAF1—kidney cancer	2.78e-05	0.00113	CbGpPWpGaD
Cevimeline—CHRM3—Gastrin-CREB signalling pathway via PKC and MAPK—RAF1—kidney cancer	2.77e-05	0.00113	CbGpPWpGaD
Cevimeline—FMO1—Metabolism—POMC—kidney cancer	2.76e-05	0.00112	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—ALAD—kidney cancer	2.72e-05	0.00111	CbGpPWpGaD
Cevimeline—CHRM1—Regulation of Actin Cytoskeleton—MAPK3—kidney cancer	2.69e-05	0.00109	CbGpPWpGaD
Cevimeline—CHRM3—Regulation of Actin Cytoskeleton—MAPK3—kidney cancer	2.68e-05	0.00109	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—ST3GAL2—kidney cancer	2.66e-05	0.00108	CbGpPWpGaD
Cevimeline—CHRM1—GPCR downstream signaling—ITPR2—kidney cancer	2.62e-05	0.00106	CbGpPWpGaD
Cevimeline—CHRM3—GPCR downstream signaling—ITPR2—kidney cancer	2.61e-05	0.00106	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—ALDH1A1—kidney cancer	2.6e-05	0.00106	CbGpPWpGaD
Cevimeline—CHRM1—Circadian rythm related genes—JUN—kidney cancer	2.56e-05	0.00104	CbGpPWpGaD
Cevimeline—CHRM1—Regulation of Actin Cytoskeleton—MAPK1—kidney cancer	2.56e-05	0.00104	CbGpPWpGaD
Cevimeline—CHRM3—Regulation of Actin Cytoskeleton—MAPK1—kidney cancer	2.55e-05	0.00104	CbGpPWpGaD
Cevimeline—CHRM1—Class A/1 (Rhodopsin-like receptors)—POMC—kidney cancer	2.5e-05	0.00101	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—PGK1—kidney cancer	2.49e-05	0.00101	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—SLC5A3—kidney cancer	2.49e-05	0.00101	CbGpPWpGaD
Cevimeline—CHRM3—Class A/1 (Rhodopsin-like receptors)—POMC—kidney cancer	2.49e-05	0.00101	CbGpPWpGaD
Cevimeline—CHRM1—Circadian rythm related genes—PTEN—kidney cancer	2.47e-05	0.00101	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—LDHB—kidney cancer	2.44e-05	0.000992	CbGpPWpGaD
Cevimeline—CYP3A4—Biological oxidations—GSTP1—kidney cancer	2.42e-05	0.000983	CbGpPWpGaD
Cevimeline—CHRM1—Regulation of Actin Cytoskeleton—KRAS—kidney cancer	2.41e-05	0.000981	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—PDHB—kidney cancer	2.41e-05	0.000979	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—GPC3—kidney cancer	2.41e-05	0.000979	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—CER1—kidney cancer	2.41e-05	0.000979	CbGpPWpGaD
Cevimeline—CHRM3—Regulation of Actin Cytoskeleton—KRAS—kidney cancer	2.41e-05	0.000978	CbGpPWpGaD
Cevimeline—CYP2D6—Biological oxidations—POMC—kidney cancer	2.4e-05	0.000976	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—GPC3—kidney cancer	2.4e-05	0.000976	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—CER1—kidney cancer	2.4e-05	0.000976	CbGpPWpGaD
Cevimeline—CYP3A4—Metapathway biotransformation—GSTP1—kidney cancer	2.38e-05	0.000969	CbGpPWpGaD
Cevimeline—CHRM1—Signaling by GPCR—ITPR2—kidney cancer	2.38e-05	0.000966	CbGpPWpGaD
Cevimeline—CHRM3—Signaling by GPCR—ITPR2—kidney cancer	2.37e-05	0.000963	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—CCBL1—kidney cancer	2.27e-05	0.000921	CbGpPWpGaD
Cevimeline—CYP3A4—Biological oxidations—GSTM1—kidney cancer	2.22e-05	0.000903	CbGpPWpGaD
Cevimeline—CHRM1—Regulation of Actin Cytoskeleton—PIK3CA—kidney cancer	2.22e-05	0.000902	CbGpPWpGaD
Cevimeline—CHRM3—Regulation of Actin Cytoskeleton—PIK3CA—kidney cancer	2.21e-05	0.000899	CbGpPWpGaD
Cevimeline—FMO1—Metabolism—PTGS2—kidney cancer	2.2e-05	0.000895	CbGpPWpGaD
Cevimeline—CHRM1—GPCR downstream signaling—ANXA1—kidney cancer	2.19e-05	0.000891	CbGpPWpGaD
Cevimeline—CYP3A4—Metapathway biotransformation—GSTM1—kidney cancer	2.19e-05	0.000891	CbGpPWpGaD
Cevimeline—CHRM3—GPCR downstream signaling—ANXA1—kidney cancer	2.19e-05	0.000888	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—CA9—kidney cancer	2.12e-05	0.00086	CbGpPWpGaD
Cevimeline—CYP3A4—Biological oxidations—CYP1A1—kidney cancer	2.11e-05	0.000856	CbGpPWpGaD
Cevimeline—CYP3A4—Metapathway biotransformation—CYP1A1—kidney cancer	2.08e-05	0.000844	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—SFRP2—kidney cancer	2.05e-05	0.000832	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—SFRP2—kidney cancer	2.04e-05	0.00083	CbGpPWpGaD
Cevimeline—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK3—kidney cancer	2e-05	0.000814	CbGpPWpGaD
Cevimeline—CHRM3—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK3—kidney cancer	2e-05	0.000812	CbGpPWpGaD
Cevimeline—CHRM1—Signaling by GPCR—ANXA1—kidney cancer	1.99e-05	0.000809	CbGpPWpGaD
Cevimeline—CHRM3—Signaling by GPCR—ANXA1—kidney cancer	1.98e-05	0.000807	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—PPAT—kidney cancer	1.96e-05	0.000798	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—GLIPR1—kidney cancer	1.96e-05	0.000798	CbGpPWpGaD
Cevimeline—FMO1—Metabolism—PTEN—kidney cancer	1.92e-05	0.000781	CbGpPWpGaD
Cevimeline—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK1—kidney cancer	1.91e-05	0.000775	CbGpPWpGaD
Cevimeline—CHRM1—GPCR ligand binding—POMC—kidney cancer	1.9e-05	0.000773	CbGpPWpGaD
Cevimeline—CHRM3—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK1—kidney cancer	1.9e-05	0.000772	CbGpPWpGaD
Cevimeline—CHRM3—GPCR ligand binding—POMC—kidney cancer	1.89e-05	0.00077	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—ACY1—kidney cancer	1.85e-05	0.000753	CbGpPWpGaD
Cevimeline—CHRM1—G alpha (q) signalling events—PIK3CA—kidney cancer	1.85e-05	0.000752	CbGpPWpGaD
Cevimeline—CHRM3—G alpha (q) signalling events—PIK3CA—kidney cancer	1.84e-05	0.000749	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—APRT—kidney cancer	1.83e-05	0.000742	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—FH—kidney cancer	1.83e-05	0.000742	CbGpPWpGaD
Cevimeline—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—kidney cancer	1.8e-05	0.000732	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—CRABP1—kidney cancer	1.8e-05	0.000732	CbGpPWpGaD
Cevimeline—CHRM3—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—kidney cancer	1.79e-05	0.00073	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—GPC3—kidney cancer	1.72e-05	0.000698	CbGpPWpGaD
Cevimeline—CHRM1—Circadian rythm related genes—TP53—kidney cancer	1.69e-05	0.000686	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—ITPR2—kidney cancer	1.67e-05	0.00068	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—CA2—kidney cancer	1.67e-05	0.000679	CbGpPWpGaD
Cevimeline—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—kidney cancer	1.65e-05	0.000672	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—CASP2—kidney cancer	1.65e-05	0.000671	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—AKAP13—kidney cancer	1.65e-05	0.000671	CbGpPWpGaD
Cevimeline—CHRM3—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—kidney cancer	1.65e-05	0.00067	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—CASP2—kidney cancer	1.65e-05	0.000669	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—AKAP13—kidney cancer	1.65e-05	0.000669	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—ALAD—kidney cancer	1.63e-05	0.000662	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—ST3GAL2—kidney cancer	1.59e-05	0.000646	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—PDHB—kidney cancer	1.58e-05	0.00064	CbGpPWpGaD
Cevimeline—CYP3A4—Biological oxidations—POMC—kidney cancer	1.57e-05	0.000638	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—ALDH1A1—kidney cancer	1.55e-05	0.000631	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—ACHE—kidney cancer	1.53e-05	0.00062	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—GSTT1—kidney cancer	1.53e-05	0.00062	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—GRB7—kidney cancer	1.51e-05	0.000614	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—GRB7—kidney cancer	1.51e-05	0.000612	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—PGK1—kidney cancer	1.49e-05	0.000605	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—SLC5A3—kidney cancer	1.49e-05	0.000605	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—CCBL1—kidney cancer	1.48e-05	0.000602	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—LDHB—kidney cancer	1.46e-05	0.000593	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—SCARB1—kidney cancer	1.44e-05	0.000587	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—PTGS1—kidney cancer	1.43e-05	0.000581	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—ITPR2—kidney cancer	1.4e-05	0.000571	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—PSMD7—kidney cancer	1.4e-05	0.00057	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—ITPR2—kidney cancer	1.4e-05	0.000569	CbGpPWpGaD
Cevimeline—FMO1—Metabolism—PIK3CA—kidney cancer	1.36e-05	0.000551	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—BCHE—kidney cancer	1.33e-05	0.00054	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—SLC5A5—kidney cancer	1.31e-05	0.000534	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—GLIPR1—kidney cancer	1.28e-05	0.000522	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—PPAT—kidney cancer	1.28e-05	0.000522	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—CTNNA1—kidney cancer	1.27e-05	0.000517	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—CTNNA1—kidney cancer	1.27e-05	0.000516	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—SLC2A1—kidney cancer	1.27e-05	0.000515	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—CA9—kidney cancer	1.27e-05	0.000514	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—HSPB1—kidney cancer	1.27e-05	0.000514	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—EIF4EBP1—kidney cancer	1.27e-05	0.000514	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—EIF4EBP1—kidney cancer	1.26e-05	0.000513	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—HSPB1—kidney cancer	1.26e-05	0.000513	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—APRT—kidney cancer	1.19e-05	0.000485	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—FH—kidney cancer	1.19e-05	0.000485	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—TSC1—kidney cancer	1.18e-05	0.000478	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—PSMD7—kidney cancer	1.18e-05	0.000478	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—ANXA1—kidney cancer	1.18e-05	0.000478	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—ANXA1—kidney cancer	1.17e-05	0.000477	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—TSC1—kidney cancer	1.17e-05	0.000477	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—PSMD7—kidney cancer	1.17e-05	0.000477	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—FLT1—kidney cancer	1.14e-05	0.000463	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—FLT1—kidney cancer	1.14e-05	0.000462	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—GPC3—kidney cancer	1.12e-05	0.000456	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—CA2—kidney cancer	1.09e-05	0.000444	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—CRABP1—kidney cancer	1.08e-05	0.000437	CbGpPWpGaD
Cevimeline—CHRM1—GPCR downstream signaling—POMC—kidney cancer	1.07e-05	0.000437	CbGpPWpGaD
Cevimeline—CHRM3—GPCR downstream signaling—POMC—kidney cancer	1.07e-05	0.000435	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—ALAD—kidney cancer	1.06e-05	0.000432	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—GSTP1—kidney cancer	1.06e-05	0.00043	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—JUNB—kidney cancer	1.06e-05	0.000429	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—PAK1—kidney cancer	1.06e-05	0.000429	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—PAK1—kidney cancer	1.05e-05	0.000428	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—JUNB—kidney cancer	1.05e-05	0.000428	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—ST3GAL2—kidney cancer	1.04e-05	0.000422	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—ALDH1A1—kidney cancer	1.02e-05	0.000413	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—ABCB1—kidney cancer	1e-05	0.000407	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—ITPR2—kidney cancer	1e-05	0.000407	CbGpPWpGaD
Cevimeline—CHRM1—Signaling by GPCR—POMC—kidney cancer	9.76e-06	0.000396	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—PGK1—kidney cancer	9.73e-06	0.000396	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—SLC5A3—kidney cancer	9.73e-06	0.000396	CbGpPWpGaD
Cevimeline—CHRM3—Signaling by GPCR—POMC—kidney cancer	9.72e-06	0.000395	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—GSTM1—kidney cancer	9.72e-06	0.000395	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—LDHB—kidney cancer	9.54e-06	0.000388	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—CYP1A1—kidney cancer	9.21e-06	0.000375	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—GSTT1—kidney cancer	9.12e-06	0.000371	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—ACHE—kidney cancer	9.12e-06	0.000371	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—SCARB1—kidney cancer	8.64e-06	0.000351	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—IGF2—kidney cancer	8.63e-06	0.000351	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—IGF2—kidney cancer	8.61e-06	0.00035	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—CDKN2B—kidney cancer	8.6e-06	0.000349	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—CDKN2B—kidney cancer	8.57e-06	0.000348	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—PTGS1—kidney cancer	8.55e-06	0.000347	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—PSMD7—kidney cancer	8.38e-06	0.000341	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—IGF1R—kidney cancer	8.35e-06	0.000339	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—IGF1R—kidney cancer	8.32e-06	0.000338	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—CA9—kidney cancer	8.28e-06	0.000336	CbGpPWpGaD
Cevimeline—CHRM1—Signaling by GPCR—RAF1—kidney cancer	8.04e-06	0.000327	CbGpPWpGaD
Cevimeline—CHRM3—Signaling by GPCR—RAF1—kidney cancer	8.02e-06	0.000326	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—BCHE—kidney cancer	7.95e-06	0.000323	CbGpPWpGaD
Cevimeline—CHRM1—GPCR downstream signaling—IL2—kidney cancer	7.94e-06	0.000323	CbGpPWpGaD
Cevimeline—CHRM3—GPCR downstream signaling—IL2—kidney cancer	7.92e-06	0.000322	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—SLC5A5—kidney cancer	7.85e-06	0.000319	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—SLC2A1—kidney cancer	7.58e-06	0.000308	CbGpPWpGaD
Cevimeline—CHRM1—Signaling by GPCR—IL2—kidney cancer	7.21e-06	0.000293	CbGpPWpGaD
Cevimeline—CHRM3—Signaling by GPCR—IL2—kidney cancer	7.19e-06	0.000292	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—CRABP1—kidney cancer	7.04e-06	0.000286	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—HIF1A—kidney cancer	6.87e-06	0.000279	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—POMC—kidney cancer	6.87e-06	0.000279	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—TSC2—kidney cancer	6.85e-06	0.000279	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—HIF1A—kidney cancer	6.85e-06	0.000278	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—TSC2—kidney cancer	6.83e-06	0.000278	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—KDR—kidney cancer	6.57e-06	0.000267	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—KDR—kidney cancer	6.55e-06	0.000266	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—ITPR2—kidney cancer	6.54e-06	0.000266	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—GSTP1—kidney cancer	6.32e-06	0.000257	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—KIT—kidney cancer	6.05e-06	0.000246	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—APC—kidney cancer	6.05e-06	0.000246	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—APC—kidney cancer	6.03e-06	0.000245	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—KIT—kidney cancer	6.03e-06	0.000245	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—ABCB1—kidney cancer	5.99e-06	0.000243	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—ACHE—kidney cancer	5.97e-06	0.000242	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—GSTT1—kidney cancer	5.97e-06	0.000242	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—GSTM1—kidney cancer	5.81e-06	0.000236	CbGpPWpGaD
Cevimeline—CHRM1—Signaling by GPCR—MAPK3—kidney cancer	5.8e-06	0.000236	CbGpPWpGaD
Cevimeline—CHRM3—Signaling by GPCR—MAPK3—kidney cancer	5.78e-06	0.000235	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—POMC—kidney cancer	5.76e-06	0.000234	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—POMC—kidney cancer	5.74e-06	0.000233	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—BRAF—kidney cancer	5.69e-06	0.000231	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—BRAF—kidney cancer	5.67e-06	0.000231	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—SCARB1—kidney cancer	5.65e-06	0.00023	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—PTGS1—kidney cancer	5.59e-06	0.000227	CbGpPWpGaD
Cevimeline—CHRM1—Signaling by GPCR—MAPK1—kidney cancer	5.52e-06	0.000224	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—CYP1A1—kidney cancer	5.51e-06	0.000224	CbGpPWpGaD
Cevimeline—CHRM3—Signaling by GPCR—MAPK1—kidney cancer	5.5e-06	0.000224	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—PSMD7—kidney cancer	5.48e-06	0.000223	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—PTGS2—kidney cancer	5.48e-06	0.000223	CbGpPWpGaD
Cevimeline—CHRM1—GPCR downstream signaling—PIK3CA—kidney cancer	5.27e-06	0.000214	CbGpPWpGaD
Cevimeline—CHRM3—GPCR downstream signaling—PIK3CA—kidney cancer	5.25e-06	0.000214	CbGpPWpGaD
Cevimeline—CHRM1—Signaling by GPCR—KRAS—kidney cancer	5.21e-06	0.000212	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—BCHE—kidney cancer	5.2e-06	0.000211	CbGpPWpGaD
Cevimeline—CHRM3—Signaling by GPCR—KRAS—kidney cancer	5.19e-06	0.000211	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—SLC5A5—kidney cancer	5.13e-06	0.000209	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—SLC2A1—kidney cancer	4.96e-06	0.000201	CbGpPWpGaD
Cevimeline—CHRM1—Signaling by GPCR—PIK3CA—kidney cancer	4.79e-06	0.000195	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—PTEN—kidney cancer	4.78e-06	0.000194	CbGpPWpGaD
Cevimeline—CHRM3—Signaling by GPCR—PIK3CA—kidney cancer	4.77e-06	0.000194	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—RAF1—kidney cancer	4.75e-06	0.000193	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—RAF1—kidney cancer	4.74e-06	0.000193	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—RELA—kidney cancer	4.73e-06	0.000192	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—RELA—kidney cancer	4.72e-06	0.000192	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—ERBB2—kidney cancer	4.7e-06	0.000191	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—ERBB2—kidney cancer	4.69e-06	0.00019	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—MTOR—kidney cancer	4.64e-06	0.000189	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—MTOR—kidney cancer	4.62e-06	0.000188	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—CDKN1B—kidney cancer	4.35e-06	0.000177	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—CDKN1B—kidney cancer	4.34e-06	0.000176	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—IL2—kidney cancer	4.26e-06	0.000173	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—IL2—kidney cancer	4.25e-06	0.000173	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—CCND1—kidney cancer	4.15e-06	0.000169	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—JUN—kidney cancer	4.14e-06	0.000168	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—CCND1—kidney cancer	4.14e-06	0.000168	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—GSTP1—kidney cancer	4.13e-06	0.000168	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—JUN—kidney cancer	4.13e-06	0.000168	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—CTNNB1—kidney cancer	4.11e-06	0.000167	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—POMC—kidney cancer	4.11e-06	0.000167	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—CTNNB1—kidney cancer	4.1e-06	0.000167	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—PTEN—kidney cancer	4.01e-06	0.000163	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—PTEN—kidney cancer	4e-06	0.000162	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—ABCB1—kidney cancer	3.91e-06	0.000159	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—GSTM1—kidney cancer	3.8e-06	0.000154	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—VEGFA—kidney cancer	3.62e-06	0.000147	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—VEGFA—kidney cancer	3.61e-06	0.000147	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—CYP1A1—kidney cancer	3.6e-06	0.000146	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—MAPK3—kidney cancer	3.43e-06	0.000139	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—MAPK3—kidney cancer	3.41e-06	0.000139	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—PIK3CA—kidney cancer	3.37e-06	0.000137	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—MYC—kidney cancer	3.33e-06	0.000135	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—MYC—kidney cancer	3.32e-06	0.000135	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—PTGS2—kidney cancer	3.28e-06	0.000133	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—MAPK1—kidney cancer	3.26e-06	0.000132	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—MAPK1—kidney cancer	3.25e-06	0.000132	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—KRAS—kidney cancer	3.08e-06	0.000125	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—KRAS—kidney cancer	3.07e-06	0.000125	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—PTEN—kidney cancer	2.86e-06	0.000116	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—PIK3CA—kidney cancer	2.83e-06	0.000115	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—PIK3CA—kidney cancer	2.82e-06	0.000115	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—TP53—kidney cancer	2.74e-06	0.000111	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—TP53—kidney cancer	2.73e-06	0.000111	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—POMC—kidney cancer	2.69e-06	0.000109	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—PTGS2—kidney cancer	2.14e-06	8.71e-05	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—PIK3CA—kidney cancer	2.02e-06	8.19e-05	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—PTEN—kidney cancer	1.87e-06	7.59e-05	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—PIK3CA—kidney cancer	1.32e-06	5.36e-05	CbGpPWpGaD
